Cisen Pharmaceutical Co Ltd (603367) — Working Capital to Net Assets Ratio
Cisen Pharmaceutical Co Ltd (603367) has a Working Capital to Net Assets ratio of 70.2% as of June 2026. Working capital of CN¥4.51 Billion (current assets of CN¥5.79 Billion minus current liabilities of CN¥1.28 Billion) is measured against net assets of CN¥6.42 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Cisen Pharmaceutical Co Ltd (603367) defensive interval to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Cisen Pharmaceutical Co Ltd Working Capital to Net Assets (2011–2025)
This chart shows how Cisen Pharmaceutical Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the ratio stands at 70.2%, reflecting working capital of CN¥4.51 Billion against net assets of CN¥6.42 Billion CNY. For the complete balance sheet picture, see 603367 total asset value.
Annual Working Capital to Net Assets for Cisen Pharmaceutical Co Ltd (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Cisen Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check financial resilience of Cisen Pharmaceutical Co Ltd to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 64.0% | CN¥3.99 Billion | CN¥6.23 Billion | CN¥5.21 Billion | CN¥1.22 Billion | ▲ +6.0 pp |
| 2024 | 58.0% | CN¥3.47 Billion | CN¥5.99 Billion | CN¥4.96 Billion | CN¥1.49 Billion | ▼ -4.4 pp |
| 2023 | 62.4% | CN¥3.60 Billion | CN¥5.77 Billion | CN¥4.97 Billion | CN¥1.37 Billion | ▼ -2.2 pp |
| 2022 | 64.7% | CN¥3.46 Billion | CN¥5.36 Billion | CN¥4.74 Billion | CN¥1.28 Billion | ▲ +6.8 pp |
| 2021 | 57.9% | CN¥2.93 Billion | CN¥5.06 Billion | CN¥4.14 Billion | CN¥1.22 Billion | ▲ +2.4 pp |
| 2020 | 55.5% | CN¥2.67 Billion | CN¥4.80 Billion | CN¥3.95 Billion | CN¥1.28 Billion | ▼ -7.8 pp |
| 2019 | 63.3% | CN¥2.90 Billion | CN¥4.57 Billion | CN¥3.78 Billion | CN¥885.54 Million | ▲ +1.1 pp |
| 2018 | 62.3% | CN¥2.59 Billion | CN¥4.15 Billion | CN¥3.60 Billion | CN¥1.01 Billion | ▲ +4.1 pp |
| 2017 | 58.2% | CN¥2.17 Billion | CN¥3.72 Billion | CN¥3.09 Billion | CN¥918.88 Million | ▲ +25.0 pp |
| 2016 | 33.1% | CN¥761.57 Million | CN¥2.30 Billion | CN¥1.50 Billion | CN¥735.54 Million | ▲ +18.2 pp |
| 2015 | 14.9% | CN¥313.16 Million | CN¥2.10 Billion | CN¥1.16 Billion | CN¥851.02 Million | ▲ +9.5 pp |
| 2014 | 5.4% | CN¥103.37 Million | CN¥1.90 Billion | CN¥806.45 Million | CN¥703.07 Million | ▼ -11.8 pp |
| 2013 | 17.3% | CN¥297.96 Million | CN¥1.73 Billion | CN¥856.77 Million | CN¥558.81 Million | ▼ -17.8 pp |
| 2012 | 35.1% | CN¥555.61 Million | CN¥1.58 Billion | CN¥1.01 Billion | CN¥452.88 Million | ▼ -6.0 pp |
| 2011 | 41.0% | CN¥551.42 Million | CN¥1.34 Billion | CN¥777.44 Million | CN¥226.02 Million | — |